Dividends Inside 
BrightSpring Health Services, Inc.
BTSG
$61.71 (+ $1.48 + 2.46%)
Last updated: 2026-08-15 00:30 UTC
BrightSpring Health Services, Inc. trades under ticker BTSG on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US10950A1060, CUSIP 10950A106. Also searched as BrightSpring Health Services.
Related researchBTSG stock priceBTSG share price10950A106BrightSpring Health Services stockBrightSpring Health Services share price
About the Company
BrightSpring Health Services, Inc. is a leading provider of comprehensive home- and community-based health services for complex populations requiring specialized and chronic care. The company delivers integrated pharmacy and provider services, including supportive care, clinical solutions, home health care, hospice, behavioral and neuro rehabilitation, and pharmacy therapy management across various settings. It serves high-need patients, such as seniors, individuals with disabilities, and those under Medicare, Medicaid, or insured programs, emphasizing quality outcomes through best-in-class services and advanced technology. Notable features include electronic health record solutions like TaskMaster Pro and QuickMAR, data analytics, telehealth, smart home monitoring, and care management platforms that enable high-tech, high-touch care. BrightSpring Health Services, Inc. focuses on connecting people with caregivers to enhance well-being in home and community environments nationwide. Founded in 1974 and headquartered in Louisville, Kentucky, it plays a vital role in the healthcare sector by supporting medically complex individuals through innovative, patient-centered approaches.
Price History
Latest News for BTSG
BrightSpring Health Services (BTSG) Is Up 10.3% After Raising 2026 Revenue Guidance And Q1 Beat – Has The Bull Case Changed?
In early May 2026, BrightSpring Health Services reported first-quarter results showing revenue of US$3.61 billion and net income of US$148.77 million, and also raised its full-year 2026 earnings guidance to expected revenues of US$14.73 billion to US$15.23 billion. The combination of outperformance in specialty pharmacy and infusion services, efficiency gains from automation, and successful home health integrations is reshaping how investors view BrightSpring’s earnings power and growth...
BrightSpring Beat And Guidance Raise Put Valuation And Debt In Focus
BrightSpring Health Services reported first quarter results that exceeded expectations, supported by specialty pharmacy and infusion therapies. Recent home health acquisitions were integrated and contributed to performance in the period. Management raised full year revenue and EBITDA guidance following the stronger quarter. BrightSpring Health Services (NasdaqGS: BTSG) has drawn attention with its latest update, as management tied the upbeat quarter to momentum in core healthcare service...
Zacks.com featured highlights include BrightSpring Health Services, StoneX and Vista
BrightSpring Health Services, StoneX and Vista have been highlighted in this Screen of The Week article.
Buy These 4 Stocks With Rising Cash Flows for Huge Gains
BTSG, SNEX, VIST and ORN stand out for improving cash flow trends, offering a resilience check beyond profits as uncertainty persists.
Buy These 4 Stocks With Robust Net Profit Margins to Boost Returns
Enhance your portfolio with BTSG, ARKO, SNEX and VIST, each exhibiting strong net profit margins and steady earnings growth.
BrightSpring Health Services’s Q1 Earnings Call: Our Top 5 Analyst Questions
BrightSpring Health Services delivered results in Q1 that surpassed Wall Street’s expectations, with the market responding positively to broad-based growth across both pharmacy and provider services. Management attributed performance to continued momentum in specialty pharmacy and infusion, as well as successful integration of recent acquisitions in home health. CEO Jon Rousseau noted, “We saw really good growth, particularly with the ramp-up of existing limited distribution drugs (LDDs), the la